REGULATORY
Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
A payer member of a key reimbursement policy panel on November 13 urged the health ministry to revise the current criteria for “indication change re-pricing” to address sales growth anticipated for Novartis’ asthma drug Xolair (omalizumab), which is expected to…
To read the full story
Related Article
REGULATORY
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
- Takeda’s CLDN18.2 ADC Earns Sakigake Tag in Japan
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





